The Top Line

The Top Line

By Fierce Life SciencesNewsBusiness News
Download on the App Store

The Top Line episodes

  • Digital Twins: Advancing Clinical Evidence Strategy (Sponsored)

    Patient digital twins give life sciences teams a framework for evaluating how an individual patient’s health trajectory could change under different treatments or scenarios. In this sponsored episode of The Top Line, host Kelly Hogan speaks with Nadea Leavitt, a clinical statistician and AI researcher at IQVIA, about the role of digital twins in clinical development and evidence generation.

    Leavitt explains the patient-specific connection that defines a digital twin, how the approach differs from external control arms, and how modeled predictions can complement observed comparator data. She reviews the spectrum of supporting analytics, from mechanistic and data-driven models to hybrid approaches that combine AI with biological knowledge and clinical constraints. The discussion also examines how IQVIA Life Science Models apply longitudinal real-world data, biomedical and clinical trial knowledge graphs, and multimodal patient information to simulate potential trajectories. Listen to the full podcast to learn more about the validation, transparency, scientific rigor and clinical plausibility required to build trust in model-generated evidence.

    See omnystudio.com/listener for privacy information.

    21 min
  • The promise of molecular gates and what comes next

    Gate Bioscience is betting that a decades-old biological mechanism could pave the way for a new class of medicines. The biotech is developing small molecules that selectively block disease-causing proteins from passing through a cellular channel called Sec61, causing them to be degraded before they can do harm.

    The approach could be particularly promising for diseases of the brain, where traditional biologics face significant delivery challenges. Gate's first publicly disclosed program targets prion disease, but the company sees opportunities across inflammation, fibrosis and other therapeutic areas.

    In this episode of "The Top Line," Fierce Biotech's Marissa Russo sits down with Gate co-founder and CEO Jordi Mata-Fink, Ph.D., to discuss the science behind the technology, how an expanded partnership with Eli Lilly is helping advance the platform and what's next as Gate prepares to move its first molecular gate drugs into the clinic.

    To learn more about the topics in this episode: 

    • Gate CEO sees expanded $870M pact with Lilly as ‘vote of confidence’ in biotech’s platform

    See omnystudio.com/listener for privacy information.

    15 min
  • Building a More Resilient Biomanufacturing Supply Network (Sponsored)

    Biomanufacturing supply networks must deliver consistency while remaining flexible enough to respond to changing demand, material availability and regional requirements. In this sponsored episode of The Top Line, Irena Luo speaks with Brandon Pence, president and chief operating officer at FUJIFILM Biosciences, about building a more reliable and adaptable global supply network. 

    Pence explains how harmonized quality systems, operating standards and raw material specifications can help manufacturing sites operate as one network and give customers more supply options. He discusses the importance of digital visibility for anticipating risk, balancing supply across approved sites and responding to changes without compromising regulatory compliance or product quality. The conversation also examines trace impurities in raw materials and how decades of data can support new solutions and digital tools for bioprocessing applications. 

    Looking ahead, Pence outlines a balanced supply model that combines global scale with regional agility, supported by supplier partnerships, scenario planning and strong quality systems. He explores how FUJIFILM Biosciences is preparing to serve customers reliably as global and regional supply models evolve. 

    See omnystudio.com/listener for privacy information.

    7 min
  • How Smarter Healthcare Environments Improve Patient Experience (Sponsored)

    Patient experience is shaped by more than clinical care. It begins with transportation, parking and wayfinding, and continues through check-in, the patient room, diagnostics and follow-up. In this sponsored episode of Podnosis, host Irena Luo speaks with Candace LeVaughn, industry principal of healthcare at Schneider Electric, and Debbie Gregory, principal healthcare innovation consulting at SSR, about designing and operating healthcare environments that better support patients and caregivers.

    The discussion examines often-unseen pressures, including nursing shortages, workplace violence, burnout, facilities staffing gaps, aging infrastructure and disconnected technologies that create delays and workarounds. The guests explore how robotics, wearables, building automation, interoperable platforms and data analytics can improve reliability and make care delivery more seamless. They also consider the next five years of healthcare design, from AI and ambient intelligence to automated transportation, power demands and grid constraints. They share why healthcare organizations should take an ecosystem-wide approach, test solutions with end users and include clinicians, staff and patients in decisions that shape the care environment.

    See omnystudio.com/listener for privacy information.

    26 min
  • Use Kidney Genetics to Strengthen Clinical Trial Design (Sponsored)

    Broad chronic kidney disease labels can obscure distinct biology, complicating patient selection, progression assumptions and treatment-signal interpretation. In this sponsored episode of The Top Line, Will Hurth speaks with Dr. Ronen Schneider, medical director of renal genetics at Natera, about the business and development implications of moving toward genotype-defined kidney disease. 

    Schneider explains how RenasightIQ connects genetic test results with clinical intake data, longitudinal laboratory measures and claims data from more than 300,000 patients. He discusses findings across FSGS and genetically defined glomerular disease, including differences in progression to end-stage kidney disease. 

    The conversation translates those insights into considerations for drug-development teams: natural-history modeling, endpoint selection, prognostic enrichment, background therapy and patient recruitment. Schneider also outlines questions teams can apply to completed studies, ongoing trials and screening populations to evaluate genetic causes, placebo-arm progression and potential variation in treatment effect. Listen to the podcast to learn how real-world genetic data can help expose hidden heterogeneity and strengthen clinical development strategy. 

    See omnystudio.com/listener for privacy information.

    16 min
  • When China Fits a Global Clinical Development Strategy (Sponsored)

    China can play several roles in a global clinical development program, from supporting a capital-efficient proof-of-concept study to contributing evidence within a multiregional clinical trial. In this sponsored episode of The Top Line, Caidya Chief Operating Officer Mike Clay and Vice President of Business Development Jinye Shen join Fierce Life Sciences’ Will Herth to discuss how sponsors can decide when and how to include China. 
     
    The conversation examines China-only, multiregional and sequenced development approaches, and how the intended use of China-generated evidence should shape the strategy. They also explain why a large patient population does not automatically equal recruitable patients, highlighting the importance of site-level feasibility, investigator networks, local treatment practices, competing trials and referral pathways. 
     
    Additionally, they discuss the risks of considering China too late, including protocol redesign, duplicated work, delayed trial starts and reduced regulatory flexibility. This conversation assesses practical perspectives on regulatory planning, bridging-study questions, operational execution, governance, data quality and the balance between local expertise and global accountability. 

    See omnystudio.com/listener for privacy information.

    18 min
  • There's more than one way to build a biotech

    As biotech companies continue to navigate a challenging funding environment, Axiom Biosciences is taking an unconventional approach to raising capital and developing new therapies.

    The company is pursuing a public listing in Hong Kong, with ambitions to eventually list on the Nasdaq. Meanwhile, it's developing several drug delivery platforms, including a stem cell therapy approach that doesn't rely on genetic modification.

    In this episode of "The Top Line," Fierce Biotech's Marissa Russo speaks with Axiom founder and CEO Remo Moomiaie-Qajar about the company's financing strategy, its approach to drug development and what's next for its clinical pipeline.

    To learn more about the topics in this episode: 

    • ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong
    • Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechs

    See omnystudio.com/listener for privacy information.

    17 min
  • When drug development gets personal

    For nearly three decades, Jigar Raythatha has helped build biotech companies and bring new medicines to patients. But in 2023, the Third Rock Ventures partner found himself on the other side of drug development when he was diagnosed with a rare form of brain cancer.

    In a remarkable coincidence, the same day Raythatha underwent the MRI that would lead to his diagnosis, Servier announced positive phase 3 results for a drug targeting his type of cancer. The treatment, now approved as Voranigo, was originally developed by Agios Pharmaceuticals, one of the first companies backed by Third Rock. Today, Raythatha takes that very drug.

    In this episode of "The Top Line," Will Maddox speaks with Raythatha about his diagnosis, how his experience as a patient has changed his perspective on drug development and the advantages his industry knowledge and connections gave him in navigating treatment.

    They also discuss the importance of early-stage biotech investment, the risks involved in developing new medicines and why Raythatha believes taking chances on promising science remains essential. 

    To learn more about the topics in this episode: 

    • Servier snags FDA approval for Voranigo, the first targeted therapy for a common type of brain tumor
    • Nuvation cancels plans to test brain cancer drug directly against Voranigo on FDA's advice
    • Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda
    • FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

     

    Thank you, IQVIA Digital, for sponsoring today's episode.

     

    See omnystudio.com/listener for privacy information.

    29 min
  • How AI turns field conversations into actionable insights (Sponsored)

    Life science field teams are a major source of customer insight, but growing complexity, limited HCP access and expanding omnichannel demands can make it difficult to turn every interaction into action. In this sponsored episode of The Top Line, host Kelly Hogan speaks with Nick Syndercombe, STEM AI lead program director at Inizio Ignite, about how AI can help connect real-world field conversations to coaching, strategic insights and stronger execution.

    Syndercombe explains how STEM AI was developed to let field teams record customer conversations for analysis by an LLM AI, producing rapid, individualized coaching feedback. For managers and leadership teams, the solution provides aggregated real-time KPI and trend analysis, along with customer sentiment on messages delivered in the field and the impact of strategy. He also discusses the importance of field-team adoption, change management, data security and moving beyond simply reporting what is happening to understanding why.

    Their conversation explores how STEM AI aims to turn HCP interactions into personalized coaching, actionable insights and strategic reporting for continuous improvement and long-term commercial impact.

    See omnystudio.com/listener for privacy information.

    17 min
  • GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing

    In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact worth up to $15 billion and the growing role of point-of-care advertising in pharmaceutical marketing.

    First, we look at GSK's big week, which included FDA approval for Jemperli in certain patients with rectal cancer, offering the possibility of avoiding chemotherapy, radiation and surgery. The company also secured a landmark approval for Hibsago, a chronic hepatitis B treatment that could deliver a functional cure for some patients. We also discuss Roche's expanded partnership with China's Hansoh Pharmaceutical, an antibody-drug conjugate deal featuring up to $15 billion in potential milestone payments.

    Then, Fierce Pharma's Zoey Becker sits down with Nicole Divinagracia, president of the Point of Care Marketing Association, to discuss the rapid growth of point-of-care advertising. Divinagracia explains what's driving that momentum, how the channel is evolving and why marketers should incorporate point of care earlier in their planning. They also explore efforts to establish more consistent measurement standards and best practices for reaching patients and healthcare professionals at critical moments in the care journey.

    To learn more about the topics in this episode: 

    • GSK’s Jemperli scores FDA approval in rectal cancer, backed by high complete response rate
    • GSK brings promise of 'functional cure' to hepatitis B finish line with FDA nod for Hibsago
    • Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact
    • Point-of-care pharma marketing spending passes $1B milestone

    See omnystudio.com/listener for privacy information.

    16 min

About The Top Line

From the publisher's feed

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's…

More shows like The Top Line

Motley Fool Hidden Gems Investing by The Motley Fool

Motley Fool Hidden Gems Investing

3,160 Listeners

WSJ Your Money Briefing by The Wall Street Journal

WSJ Your Money Briefing

1,703 Listeners

WSJ What’s News by The Wall Street Journal

WSJ What’s News

4,349 Listeners

Masters in Business by Bloomberg

Masters in Business

2,167 Listeners

The McKinsey Podcast by McKinsey & Company

The McKinsey Podcast

382 Listeners

Odd Lots by Bloomberg

Odd Lots

2,125 Listeners

Stephanomics by Bloomberg

Stephanomics

349 Listeners

WSJ Tech News Briefing by The Wall Street Journal

WSJ Tech News Briefing

1,635 Listeners

HBR IdeaCast by Harvard Business Review

HBR IdeaCast

132 Listeners

FT Tech Tonic by Financial Times

FT Tech Tonic

102 Listeners

Masters of Scale by WaitWhat

Masters of Scale

3,982 Listeners

Bold Names by The Wall Street Journal

Bold Names

1,426 Listeners

The Readout Loud by STAT

The Readout Loud

338 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

33 Listeners

HBR On Leadership by Harvard Business Review

HBR On Leadership

155 Listeners